Background and Aims: Pregnancy in women with a prosthetic heart valve is considered high risk, primarily due to the need for effective anticoagulation. However, data on the relationship between anticoagulation practices and pregnancy outcomes are very limited. Methods: The Registry of Pregnancy and Cardiac disease is a global registry that prospectively enrolled pregnancies in women with a prosthetic heart valve between January 2018 and April 2023. Detailed data on anticoagulation, including dosage and monitoring, and cardiovascular, pregnancy, and perinatal outcomes were collected. Results: In total, 613 pregnancies were included of which 411 pregnancies were in women with a mechanical valve and 202 were in women with a biological valve. The chance of an uncomplicated pregnancy with a live birth in women with a mechanical valve was 54%, compared with 79% in women with a biological valve (P < .001). Thromboembolic and haemorrhagic complications most frequently occurred when low-molecular weight heparin (LMWH)–based regimens were used. Valve thrombosis occurred in 24 (6%) women, and a prosthetic valve in mitral position was associated with valve thrombosis (odds ratio 3.3; 95% confidence interval 1.9–8.0). A thromboembolic event occurred in 12 (10%) women with anti-Xa monitoring and in 9 (21%) women without (P = .060). Foetal death occurred in 20% of all pregnancies. Conclusions: More favourable outcomes were found in women with a biological valve compared with a mechanical valve. In women with a mechanical valve, the use of LMWH was associated with an increased risk of thromboembolic complications. A mitral prosthetic valve was identified as a predictor for valve thrombosis. The benefit could not be confirmed nor refuted, in terms of reduced thromboembolic events, from using anti-Xa level monitoring in women on LMWH.
27 June 2025 in European Heart Journal - Quality of Care and Clinical Outcomes
Aims: The risk of pregnancy in women with heritable thoracic aortic disease (HTAD) is estimated to be high, but supporting data are scarce. The aim of this study is to prospectively investigate pregnancy outcomes to improve patient management and care. Methods and results: The Registry of Pregnancy and Cardiac disease (ROPAC) III is a prospective global registry including pregnant women with known aortic pathology between 2018 and 2023. Cardiac, obstetric and fetal outcomes, beta-blocker use, and the impact of breastfeeding were investigated. Additionally, changes in aortic diameters were assessed. In total, 176 pregnancies in 170 women (mean age 32 years, 56% primigravida) with HTAD were included: 122 with Marfan syndrome, 14 with Loeys–Dietz syndrome, 10 with ACTA2 variants, and 30 with other diagnoses. There was no maternal or neonatal mortality, while six (3.4%) fetal deaths occurred. Thirteen (7.6%) women suffered a major adverse cardiac event (MACE), including six (3.5%) aortic dissections (three during and three after pregnancy). Beta-blockers were used throughout pregnancy by 83 (47%) women. Women taking beta-blockers did not experience less MACE, aortic dissection, or aortic growth. Breastfeeding women had a significantly lower occurrence of MACE compared with non-breastfeeding women. The aortic diameter showed significant growth during pregnancy. Conclusion: The aortic dissection rate in this cohort of women with HTAD diagnosis prior to pregnancy, under surveillance in specialized clinics, was lower than previously reported. Our results suggest that pregnancy might have some effect on aortic growth and dissections did occur. This warrants close monitoring, also after delivery. Importantly, we found no association between breastfeeding and post-partum complications.
20 June 2025 in European Journal of Cardio-Thoracic Surgery
OBJECTIVES: Heart valve replacement during pregnancy is sometimes unavoidable, and the need for anticoagulation further complicates these procedures. Our study describes cases of valve replacement in pregnancy enrolled in the Registry Of Pregnancy And Cardiac disease (ROPAC) III and gives an overview of the published literature. METHODS: We performed a systematic review with new data from the ROPAC III and data available in the literature. ROPAC III is a global, prospective, observational registry that included pregnant women with 1 or more prosthetic valves between January 2018 and April 2023. Electronic databases were searched for studies enrolling pregnant women who underwent valve replacement during pregnancy with a fetus in utero. The primary outcomes were maternal and fetal death. Mixed-effect logistic regression models were used to identify predictors for maternal and fetal mortality. RESULTS: A valve replacement was performed in 11 pregnancies. The mother and fetus died in 1 case, and in 2 cases, reversible postoperative complications occurred. We found 74 cases in the literature and calculated an overall maternal and fetal death rate of 9% and 34%, respectively. All maternal deaths occurred in women with a replacement of a prosthetic valve in mitral position. We found valve replacement in the 1st trimester (OR 10.0) and acute malfunctioning of an existing prosthetic valve (OR 19.7) as predictors for maternal mortality, and replacement of an existing prosthetic valve (OR 4.8) as predictor for fetal mortality. CONCLUSIONS: Valve replacement during pregnancy carries a high maternal and fetal death, especially in women who need a replacement of an existing prosthetic valve.
2 May 2024 in Acta Obstetricia et Gynecologica Scandinavica
Introduction: Recurrent postmenopausal bleeding (PMB) occurs in 6%–25% of postmenopausal women who have experienced a previous episode of PMB. The question of whether recurrent PMB leads to a higher risk of endometrial cancer (EC) in comparison to a single episode of PMB is, however, controversial. Furthermore, little is known about predictive factors for recurrent PMB.Material and Methods: A multicenter prospective cohort study was conducted over a 5‐year period in four hospitals in the Netherlands. Women with PMB undergoing endometrial sampling and aged 40 years and older were included. Occurrence of recurrent PMB was retrospectively determined. Primary outcomes included (1) the incidence of recurrent PMB and (2) differences in pathological findings between patients with a single episode vs recurrent PMB. Secondary outcomes included (1) the association between diagnosis of benign polyps at first PMB and pathological findings at recurrent PMB and (2) factors predictive for recurrent PMB.Results: A total of 437 women with PMB were included, of whom 360 were at risk of recurrent PMB. With a median follow‐up of 61 months (IQR (Interquartile range) 44–73), 26.4% experienced recurrent PMB. Patients with recurrent PMB were more often diagnosed with benign polyps (34.7% vs. 25.1%, p‐value 0.015) and less frequently with a malignancy (5.3% vs. 17.8%, p‐value 0.015), compared to patients with a single episode of PMB. Benign polyps at initial PMB were not associated with a (pre)malignancy at recurrence (OR 4.16, 95% CI 0.75–23.03). Predictive factors for recurrent PMB included use of hormone replacement therapy (HRT) (OR 3.32, 95% CI 1.64–6.72), and benign polyps at initial PMB (OR 1.80, 95% CI 1.07–3.04).Conclusions: Recurrent PMB is common in women with a previous episode of PMB. Compared to patients with a single episode of PMB, patients with recurrent PMB and benign histological outcomes at accurate workup during their first episode were less often diagnosed with malignancies and more frequently with benign polyps. Benign polyps at first PMB are predictive for recurrent PMB, but not for a higher risk of (pre)malignancy.
Aims: Data on cardiovascular outcomes and aortic growth in pregnant women with Turner syndrome are limited. We examine the cardiovascular and pregnancy outcomes in these women and analyse aortic growth throughout pregnancy. Methods and results: The Registry of Pregnancy and Cardiac Disease III is a global, prospective, observational registry that enrolled pregnancies of women pre-pregnancy known with Turner syndrome from 2018 to 2023. We compared baseline characteristics and outcomes between women at low and moderate-to-high risk of aortic events and between women with a pregnancy conceived with assisted reproductive technology (ART) and those who conceived spontaneously. Linear mixed models were used to analyse aortic growth with the examinations and aortic diameter as independent and dependent variables, respectively, and random effects were used to account for repeated measurements. In total, 47 pregnancies were included, of which 49% were classified as moderate-to-high risk (bicuspid aortic valve, aortic dilatation, and/or hypertension), and 60% occurred after ART. No maternal mortality or dissection occurred during or after pregnancy. Hypertensive disorders occurred in 26%. No differences in pregnancy outcomes were found when comparing the risk groups, but women who conceived after ART were delivered by Caesarean section more often (65 vs. 42%; P = 0.011) and had earlier deliveries (38 vs. 39 weeks; P = 0.010) compared to women with a spontaneous conception. We observed a significant aortic growth at the sinus of Valsalva during pregnancy; however, aortic diameters during a median follow-up of 7 months were not different from pre-pregnancy diameters. Conclusion: Pregnancy outcomes in women known with Turner syndrome are better than reported before. While aortic dilatation may occur during pregnancy, it appears reversible postpartum. Attention for hypertension remains warranted.